UTHR UNITED THERAPEUTICS Corp
Price (delayed)
$290.85
Market cap
$13.06B
P/E Ratio
11
Dividend/share
N/A
EPS
$26.44
Enterprise value
$11.67B
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and
Highlights
The debt has plunged by 57% YoY and by 25% from the previous quarter
The company's EPS rose by 26% YoY and by 9% QoQ
Key stats
What are the main financial stats of UTHR
Market
Valuations
Earnings
Shares outstanding
44.91M
Market cap
$13.06B
Enterprise value
$11.67B
Price to earnings (P/E)
11
Price to book (P/B)
2.02
Price to sales (P/S)
4.57
EV/EBIT
7.37
EV/EBITDA
7.05
EV/Sales
4.05
Revenue
$2.88B
Gross profit
$2.57B
Operating income
$1.38B
Net income
$1.2B
EBIT
$1.58B
EBITDA
$1.65B
Free cash flow
$1.08B
Per share
Balance sheet
Liquidity
EPS
$26.44
EPS diluted
$24.64
Free cash flow per share
$23.91
Book value per share
$144.34
Revenue per share
$63.66
TBVPS
$160.44
Total assets
$7.36B
Total liabilities
$920M
Debt
$300M
Equity
$6.44B
Working capital
$3.14B
Debt to equity
0.05
Current ratio
5.25
Quick ratio
4.8
Net debt/EBITDA
-0.84
Margins
Efficiency
Dividend
EBITDA margin
57.5%
Gross margin
89.2%
Net margin
41.5%
Operating margin
47.9%
Return on assets
17.3%
Return on equity
20.3%
Return on invested capital
31.8%
Return on capital employed
23.9%
Return on sales
55%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UTHR stock price
How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-1.88%
1 week
2.15%
1 month
-8.17%
1 year
23.27%
YTD
-17.57%
QTD
-5.65%
Financial performance
How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.88B
Gross profit
$2.57B
Operating income
$1.38B
Net income
$1.2B
Gross margin
89.2%
Net margin
41.5%
The company's gross profit rose by 24% YoY and by 4.7% QoQ
The company's revenue rose by 24% YoY and by 4.4% QoQ
UNITED THERAPEUTICS's net income has increased by 21% YoY and by 8% QoQ
The operating income has grown by 16% YoY and by 8% from the previous quarter
Growth
What is UNITED THERAPEUTICS's growth rate over time
Valuation
What is UNITED THERAPEUTICS stock price valuation
P/E
11
P/B
2.02
P/S
4.57
EV/EBIT
7.37
EV/EBITDA
7.05
EV/Sales
4.05
The company's EPS rose by 26% YoY and by 9% QoQ
The stock's P/E is 20% below its 5-year quarterly average of 14.1 and 14% below its last 4 quarters average of 13.0
UTHR's price to book (P/B) is 15% lower than its last 4 quarters average of 2.4 and 2.4% lower than its 5-year quarterly average of 2.1
The equity has increased by 8% year-on-year and by 6% since the previous quarter
The company's revenue rose by 24% YoY and by 4.4% QoQ
The stock's P/S is 12% below its last 4 quarters average of 5.3 and 7% below its 5-year quarterly average of 5.0
Efficiency
How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 39% YoY and by 10% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 19% YoY and by 7% QoQ
The ROE has grown by 15% YoY and by 6% from the previous quarter
The company's return on sales fell by 4% YoY
Dividends
What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UTHR.
Financial health
How did UNITED THERAPEUTICS financials performed over time
The company's total liabilities fell by 22% YoY and by 10% QoQ
The current ratio has grown by 19% YoY and by 15% from the previous quarter
The debt is 95% less than the equity
UNITED THERAPEUTICS's debt to equity has shrunk by 58% YoY and by 29% QoQ
The debt has plunged by 57% YoY and by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.